NEW YORK (GenomeWeb) – Researchers with the I-SPY 2 TRIAL have determined that a pair of phosphoproteins could identify triple-negative breast cancer (TNBC) patients likely to respond to the tyrosine kinase inhibitor neratinib.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Be the first to comment